# **Product** Data Sheet

### COX-2-IN-2

Cat. No.: HY-101655

CAS No.: 134729-13-8

Molecular Formula:  $C_{17}H_{12}FN_3O_2S$ 

Molecular Weight: 341.36
Target: COX

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

#### **BIOLOGICAL ACTIVITY**

Description	COX-2-IN-2 is a selective and inducible COX2 inhibitor with an IC $_{50}$ of 0.24 $\mu$ M. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.
IC <sub>50</sub> & Target	COX-2 240 nM (IC <sub>50</sub> )
In Vitro	COX-2-IN-2 shows no COX-1 inhibition even at $100\mu M^{[1]}$ .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	COX-2-IN-2 has oral ED $_{50}$ values of 0.030 and 0.47mg/kg on adjuvant-induced arthritis and collagen-induced arthritis, respectively, and an ED $_{30}$ value of 7.4mg/kg in the yeast-induced hyperalgesia (Randall-Selitto) assay. COX-2-IN-2 shows good analgesic activity and no ulcerogenicity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **PROTOCOL**

Kinase Assay <sup>[1]</sup>

hCOX1 or hCOX2 is preincubated with COX2-IN-2 in 0.1 M Tris-HCl buffer containing 2 μM hematin and 5 mM L-tryptophan at 30°C for 5 min, followed by a 5 min incubation with arachidonic acid. The enzyme reaction is stopped by the addition of 1 N HCl. The PGE2 formed is extracted with EtOAc and measured by RIA<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration <sup>[1]</sup> Rats: Ten male Sprague Dawley rats are used per group. A suspension of 0.5% brewer's yeast in 0.5% methyl cellulose is injected into the right hind paw. The pain threshold us determined 3h after yeast injection. COX-2-IN-2 is given orally 2h after yeast injection. The pain threshold in the treated rats are compared with that in the control rats<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Tsuji K, et al. Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem Pharm Bull (1997),

45(6), 987-995.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com